Hepatitis B Virus (HBV)

Category: Heart Failure (Page 2)

A Review of Why and How We May Use β-Blockers in Congestive Heart Failure: Mechanisms of Benefits

Heart Rates Because the first trials of β-blockers were inspired by the tachycardias found in many patients with CHF, and since those with the fastest pretreated heart rates had the most dramatic response, it was assumed that slowing of the heart rate may allow more energy to be used for contractile work and renew a […]

A Review of Why and How We May Use β-Blockers in Congestive Heart Failure: Effects of β-Blockers on Mortality

In the 3-year follow-up report by Swedberg et al in 1979 on their 24 patients with severe CHF, there was a suggestion of a decrease in mortality when compared with an historically comparable group of 13 patients. In 1985, Anderson et al noted that with metoprolol and no ACE inhibitors by intention-to-treat calculations, there was […]

A Review of Why and How We May Use β-Blockers in Congestive Heart Failure: Bisoprolol and Bucindolol Studies

In 1988, Brodsky et al found that 16 of 32 patients with DCM who also had ventricular tachycardia or fibrillation improved their exercise duration while taking β-blockers (Table 2). In 1993, Waagstein et al10 reported on a 5-year placebo-controlled metoprolol in a DCM trial of 383 subjects with class 2 or 3 CHF from 33 […]

A Review of Why and How We May Use β-Blockers in Congestive Heart Failure

Package inserts for all the β-blockers contain a contraindication statement about their use in patients with congestive heart failure (CHF). However, in 1975, a Swedish group used them successfully in patients with severe CHF due to idiopathic dilated cardiomyopathy (DCM). Resting tachycardia was the justification for their use. This study and their optimistic follow-up reports […]

Tags